# US 6,726,912 B1 · Papillomavirus polyprotein constructs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,912 B1
- Document ID: US6726912B1
- Status: Granted
- Kind: B1
- Application number: 10/011,749
- Filed: 2001-12-11
- Granted: 2004-04-27
- Earliest claimed: 1995-07-27
- Assignees: CSL Limited; The University of Queensland of St. Lucia
- Inventors: Elizabeth Ann Webb; Mary Brigid Margetts; John Cooper Cox; Ian Frazer; Nigel Alan John McMillan; Mark Philip Williams; Margaret Bridget Holland Moloney; Stirling John Edwards
- Web page: https://patentgrep.com/patent/US6726912B1

## CPC

- C07K 14/005: from viruses
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A papillomavirus polyprotein construct comprises at least two amino acid sequences fused directly or indirectly together, each of the sequences being the sequence of an early ORF protein of papillomavirus or an immunogenic variant or fragment thereof, and at least one of said sequences being other than the E6 or E7 protein sequence or an immunogenic variant or fragment thereof. Nucleic acid molecules encoding the polyprotein construct, prophylactic or therapeutic compositions comprising the polyprotein construct or the nucleic acid molecule, and methods for eliciting an immune response against papillomavirus in a host animal are also provided.

## Claims

### Claim 1

A nucleic acid molecule which encodes a polyprotein construct comprising at least two amino acid sequences fused directly or indirectly together, each of said sequences being the sequence of an early open reading frame (ORF) protein of papillomavirus (PV), or an immunogenic variant thereof, or a non-full length fragment that is a deletion mutant of the early ORF protein corresponding to at least 50% of the full length wild-type amino acid sequence, wherein
i. said construct does not contain both an E6 and an E7 PV protein sequence;
ii. said construct does not contain an L2 PV protein sequence; and
iii. when said construct consists of only two early ORF PV protein sequences, said protein sequences are from the same PV type.

### Claim 2 (depends on 1)

A recombinant DNA molecule comprising an expression control sequence operatively linked to a nucleic acid molecule according to claim 1.

### Claim 3 (depends on 2)

A recombinant DNA molecule according to claim 2, wherein said expression control sequence comprises promoter and initiator sequences, the sequence of nucleotides encoding the polyprotein construct being located in a single translational frame 3′ to the promoter and initiator sequences, and a termination sequence located 3′ to said sequence of nucleotides.

### Claim 4 (depends on 2)

A recombinant DNA cloning vector comprising a recombinant DNA molecule according to claim 2.

### Claim 5 (depends on 4)

A recombinant DNA cloning vector according to claim 4, wherein said vector is a plasmid.

### Claim 6 (depends on 2)

A host cell transformed with a recombinant DNA molecule according to claim 2.

### Claim 7 (depends on 6)

A host cell according to claim 6, wherein said host cell is E. coli.

### Claim 8 (depends on 1)

A composition comprising a nucleic acid molecule according to claim 1, together with a pharmaceutically acceptable carrier and/or diluent.

### Claim 9 (depends on 1)

A method for eliciting an immune response against PV in a host animal, which method comprises administering to the host animal an immunologically effective amount of a nucleic acid molecule according to claim 1.

### Claim 10 (depends on 4)

A host cell according to claim 4, wherein said host cell is E. coli.

### Claim 11 (depends on 1)

A nucleic acid molecule according to claim 1, wherein said sequences of said polyprotein construct are sequences of early ORF proteins of human Pv.

### Claim 12 (depends on 11)

A nucleic acid molecule according to claim 11, wherein said early ORF sequences are selected from the group consisting of the E1, E2, E3, E4, E5 (E5a, E5b), E6, E7, and E8 proteins of PV.

### Claim 13 (depends on 12)

A nucleic acid molecule according to claim 12, wherein said polyprotein construct is selected from the group consisting of:
a. E6/E4;
b. E6/E5a/E4;
c. E2/E5b;
d. E2/E1/E5b;
e. E2/E5a/E5b; and
f. E2/E1/E5a/E5b.

### Claim 14 (depends on 1)

A nucleic acid molecule according to claim 1, wherein said polyprotein construct further comprises one or more linker sequences between and/or before and/or after said amino acid sequences.

### Claim 15 (depends on 14)

A nucleic acid molecule according to claim 14, wherein said linker sequence(s) comprise from 1 to 5 amino acid residues.

### Claim 16 (depends on 1)

A nucleic acid molecule according to claim 1, wherein said polyprotein construct further comprises a tag protein or peptide moiety fused or otherwise coupled thereto.

### Claim 17 (depends on 16)

A nucleic acid molecule according to claim 16, wherein said tag moiety is selected from the group consisting of (His)6, glutathione-S-transferase (GST), and FLAG.

### Claim 18 (depends on 1)

A nucleic acid molecule according to claim 1, wherein said polyprotein construct further comprises an adjuvant moiety fused or otherwise coupled thereto.

### Claim 19 (depends on 18)

A nucleic acid molecule according to claim 18, wherein said adjuvant moiety is selected from the group consisting of diphtheria toxin, cholera toxin, E. coli heat labile toxin (LT), and a non-toxic derivative thereof.

### Claim 20 (depends on 19)

A nucleic acid molecule according to claim 19, wherein said non-toxic derivative is selected from the group consisting of the holotoxoid of cholera toxin, the B-subunit of cholera toxin, the holotoxoid of LT, and the B-subunit of LT.

### Claim 21 (depends on 1)

A nucleic acid molecule according to claim 1, wherein said polyprotein construct further comprises a lipid binding region.

### Claim 22 (depends on 21)

A nucleic acid molecule according to claim 21, wherein said lipid binding region is an influenza haemagglutinin tail.

### Claim 23 (depends on 22)

A nucleic molecule according to claim 22, wherein said lipid binding region is an influenza haemagglutinin tail.
